As many as 45% of Americans have a chronic disease. Shared cardiometabolic risk factors contribute to related conditions, such as cardiovascular disease, poor glycemic control, chronic kidney disease, fatty liver disease, and common endocrine disorders. As evidence demonstrating the interrelationships between chronic cardiometabolic diseases continues to expand, establishing a personalized approach to reduce risk is crucial. This episode is with Quest Diagnostics® experts Maeson Latsko, PhD, Clinical and Education Specialist, and Dr Marc Penn, founder and chief medical officer for Cleveland Heart Lab at the Quest Cardiometabolic Center of Excellence™ in Cleveland, Ohio.  Dr Penn is also a board-certified cardiologist and director of research at Summa Cardiovascular Institute. This episode will Review how the risk factors for cardiovascular disease have changed (1:15) Discuss how the cardiometabolic approach brings attention to related conditions, such as cardiovascular disease, chronic kidney disease, fatty liver disease, and dysglycemia (3:00) Describe the importance of evaluating endocrine disorders when assessing risk for cardiometabolic conditions (6:45) Walk through a clinical example of how to implement the cardiometabolic approach (8:50) Discuss how to implement prevention with clinical solutions to improve patient care (3:45, 14:00) The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions. Date: 2/2025 Speaker(s): Maeson S Latsko, PhD; Marc Penn, MD, PhD Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Mouris Saghir, PhD References:  Fuster V, García-Álvarez A, Devesa A, et al. Influence of Subclinical Atherosclerosis Burden and Progression on Mortality. J Am Coll Cardiol. 2024;84(15):1391-1403. doi:10.1016/j.jacc.2024.06.045 Correia LC. Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. Arq Bras Cardiol. 2016;106(3):247-249. doi:10.5935/abc.20160033 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563   Additional Resources: Website: Cardiometabolic disease | Quest Diagnostics